Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model

OBJECTIVE: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of...

Descripción completa

Detalles Bibliográficos
Autores principales: Putri, Septiara, Nugraha, Ryan R., Pujiyanti, Eka, Thabrany, Hasbullah, Hasnur, Hanifah, Istanti, Novita D., Evasari, Diah, Afiatin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724412/
https://www.ncbi.nlm.nih.gov/pubmed/36474238
http://dx.doi.org/10.1186/s13104-022-06252-4
Descripción
Sumario:OBJECTIVE: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. RESULTS: Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13104-022-06252-4.

Ejemplares similares